ECM
OCUL icon

Endurant Capital Management’s Ocular Therapeutix OCUL Stock Holding History

Endurant Capital Management’s Portfolio OCUL Stock Details OCUL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-353,707
Closed -$1.11M – 44
2023
Q3 		$1.11M Sell
353,707
-14,731
-4% -$60.3K 1% 29
2023
Q2 		$1.9M Sell
368,438
-144,306
-28% -$858K 1.66% 19
2023
Q1 		$2.7M Sell
512,744
-551,209
-52% -$2.62M 1.39% 19
2022
Q4 		$2.99M Sell
1,063,953
-342
-0% -$1.13K 1.21% 20
2022
Q3 		$4.42M Buy
1,064,295
+304,067
+40% +$1.53M 1.44% 22
2022
Q2 		$3.06M Sell
760,228
-163,735
-18% -$619K 1.07% 25
2022
Q1 		$4.57M Buy
923,963
+206,820
+29% +$1.15M 1.2% 22
2021
Q4 		$5M Buy
717,143
+106,742
+17% +$829K 1.21% 27
2021
Q3 		$6.1M Buy
610,401
+39,431
+7% +$443K 1.39% 23
2021
Q2 		$8.1M Buy
570,970
+132,037
+30% +$2.01M 2.23% 12
2021
Q1 		$7.2M Buy
438,933
+148,468
+51% +$2.86M 1.88% 24
2020
Q4 		$6.01M Sell
290,465
-546,672
-65% -$8.12M 2.17% 17
2020
Q3 		$6.37M Buy
837,137
+81,807
+11% +$679K 1.88% 15
2020
Q2 		$6.29M Buy
+755,330
New +$5.01M 0.35% 16
2019
Q2 		– Sell
-716,124
Closed -$2.84M – 70
2019
Q1 		$2.84M Buy
716,124
+483,397
+208% +$1.94M 1.12% 28
2018
Q4 		$926K Sell
232,727
-69,426
-23% -$383K 0.49% 37
2018
Q3 		$2.08M Buy
302,153
+159,378
+112% +$1M 0.92% 32
2018
Q2 		$964K Sell
142,775
-35,686
-20% -$245K 0.42% 45
2018
Q1 		$1.16M Buy
+178,461
New +$1M 0.43% 52

Other funds holding OCUL

DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
SR
Summer Road West Palm Beach, Florida $142M AUM 43.61% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
DAM
Deltec Asset Management New York $545M AUM 33.4% 1-Year Est. Return

Endurant Capital Management's OCUL Position: Q4 2023 in Review

Endurant Capital Management sold out of Ocular Therapeutix (OCUL) in Q4 2023, closing a stake of 353,707 shares — an estimated $1.11M sold.

Endurant Capital Management first reported a position in OCUL in Q1 2018 and held it in 19 quarters. The position peaked at $8.1M in Q2 2021. 118 funds tracked by Wall St. Rank hold OCUL as of Q4 2023.

  • Endurant Capital Management reported no remaining Ocular Therapeutix position as of Q4 2023 after selling out during the quarter.
  • Endurant Capital Management sold 353,707 Ocular Therapeutix shares in Q4 2023, an estimated $1.11M.
  • Endurant Capital Management first reported a position in Ocular Therapeutix in Q1 2018 and held it in 19 quarters.
  • Endurant Capital Management's Ocular Therapeutix position peaked at $8.1M in Q2 2021.
  • 118 funds tracked by Wall St. Rank held Ocular Therapeutix as of Q4 2023.

Based on Endurant Capital Management's 13F filing for Q4 2023, filed 14 Feb 2024.